Cholesterol and COVID-19—therapeutic opportunities at the host/virus interface during cell entry
Open Access
- 22 February 2024
- journal article
- review article
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7 (5) , e202302453
Abstract
The rapid development of vaccines to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has been critical to reduce the severity of COVID-19. However, the continuous emergence of new SARS-CoV-2 subtypes highlights the need to develop additional approaches that oppose viral infections. Targeting host factors that support virus entry, replication, and propagation provide opportunities to lower SARS-CoV-2 infection rates and improve COVID-19 outcome. This includes cellular cholesterol, which is critical for viral spike proteins to capture the host machinery for SARS-CoV-2 cell entry. Once endocytosed, exit of SARS-CoV-2 from the late endosomal/lysosomal compartment occurs in a cholesterol-sensitive manner. In addition, effective release of new viral particles also requires cholesterol. Hence, cholesterol-lowering statins, proprotein convertase subtilisin/kexin type 9 antibodies, and ezetimibe have revealed potential to protect against COVID-19. In addition, pharmacological inhibition of cholesterol exiting late endosomes/lysosomes identified drug candidates, including antifungals, to block SARS-CoV-2 infection. This review describes the multiple roles of cholesterol at the cell surface and endolysosomes for SARS-CoV-2 entry and the potential of drugs targeting cholesterol homeostasis to reduce SARS-CoV-2 infectivity and COVID-19 disease severity.Keywords
This publication has 174 references indexed in Scilit:
- Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19JAMA, 2023
- Insight into the role of clathrin‐mediated endocytosis inhibitors in SARS‐CoV‐2 infectionReviews in Medical Virology, 2022
- A population-based cohort study of sex and risk of severe outcomes in covid-19European Journal of Epidemiology, 2022
- COVID‐19 metabolism: Mechanisms and therapeutic targetsMedcomm, 2022
- Dysregulation of the mevalonate pathway during SARS‐CoV‐2 infection: An in silico studyJournal of Medical Virology, 2020
- Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19JAMA, 2020
- In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRsJournal of Medical Virology, 2020
- Annexin A6 modulates TBC1D15/Rab7/StARD3 axis to control endosomal cholesterol export in NPC1 cellsCellular and Molecular Life Sciences, 2019
- HDL in Infectious Diseases and Sepsis2014
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004